v3.20.1

Total revenues and other income - Disaggregation of revenues (Details) - EUR (€) € in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees | € 812,058 | € 196,486 | € 71,971
Milestone payments | 2,878 | 73,394 | 42,950
Reimbursement income | 19,900 | 8,722 | 3,273
Other revenues | 10,150 | 10,233 | 8,893
Revenues | 844,985 | 288,836 | 127,087
Research and Development Segment |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Revenues | 834,901 | 278,666 | 118,262
Fee for services segment |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Revenues | 10,084 | 10,170 | 8,825
Other |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Reimbursement income |  | 16 |
Other revenues | 66 | 63 |
Over time | Fee for services segment |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Other revenues | 10,084 | 10,170 |
IFRS 15 |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  | 196,486 |
Milestone payments |  | 73,394 |
Reimbursement income |  | 8,722 |
Other reimbursement income |  | 16 |
Other revenues |  | 10,233 |
Revenues |  | 288,836 |
IFRS 15 | Other |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Other revenues |  | 63 |
IFRS 15 | Over time | Fee for services segment |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Other revenues |  | 10,170 |
IFRS 15 | Gilead | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  | 96,809 |
Milestone payments |  | 27,623 |
IFRS 15 | AbbVie | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  | 52,176 |
Milestone payments |  | 36,771 |
Reimbursement income |  | 989 |
IFRS 15 | Novartis | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Reimbursement income |  | 7,718 |
IFRS 15 | Novartis | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  | 47,500 |
IFRS 15 | Servier | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Milestone payments |  | 9,000 |
IAS18 |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  |  | 71,971
Milestone payments |  |  | 42,950
Reimbursement income |  |  | 3,273
Other reimbursement income |  |  | 4
Other revenues |  |  | 8,893
Revenues |  | 232,800 | 127,087
IAS18 | Other |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Other revenues |  |  | 68
IAS18 | Over time | Fee for services segment |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Other revenues |  |  | 8,825
IAS18 | Gilead | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  |  | 71,333
IAS18 | Gilead | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Milestone payments |  |  | 9,354
IAS18 | AbbVie | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Milestone payments |  |  | 33,596
Reimbursement income |  |  | 453
IAS18 | Servier | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  |  | 638
IAS18 | Servier | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Reimbursement income |  |  | € 2,816
Gilead collaboration agreement for GLPG 1690 | Gilead | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees | 666,968 |  |
Collaboration agreement for filgotinib | Gilead | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees | 62,602 | 96,809 |
Milestone payments | (21,187) | 27,623 |
Collaboration agreement for CF | AbbVie | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees | 1,569 | 52,176 |
Milestone payments | 24,065 | 36,771 |
Reimbursement income | 723 | 989 |
Servier collaboration agreement for osteoarthritis | Servier | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Milestone payments |  | 9,000 |
Gilead collaboration agreement for drug discovery platform | Gilead | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees | 80,918 |  |
Collaboration agreement for MOR106 | Novartis | Over time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Reimbursement income | € 19,177 | 7,718 |
Collaboration agreement for MOR106 | Novartis | Point in time |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Recognition of non-refundable upfront payments and license fees |  | € 47,500 |

X
- Definition Amount of revenue from milestone payments. + References No definition available. + Details
Name: | glpg_MilestonePayments
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of other reimbursement income. + References No definition available. + Details
Name: | glpg_OtherReimbursementIncome
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue from the recognition of non-refundable upfront payments. + References No definition available. + Details
Name: | glpg_RecognitionOfNonRefundableUpfrontPayments
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue from reimbursement income. + References No definition available. + Details
Name: | glpg_ReimbursementIncome
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_112_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_OtherRevenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Expiry date 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants. Effective 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 28 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 23 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23_a&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 32 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_32&doctype=Standard -URIDate 2019-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 33 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_33_a&doctype=Standard -URIDate 2019-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 34 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_34&doctype=Standard -URIDate 2019-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 82 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_82_a&doctype=Standard -URIDate 2019-03-27 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 103 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_103&doctype=Standard -URIDate 2019-03-27 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 102 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_102&doctype=Standard -URIDate 2019-03-27 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2019-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2019-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2019-03-27 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2019-03-27 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B10 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=glpg_ResearchAndDevelopmentSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=glpg_FeeForServicesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=glpg_Ifrs15Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_AbbvieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_ServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=glpg_Ias18StandardMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForGlpg1690Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForCfMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForOsteoarthritisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_GileadCollaborationAgreementForDrugDiscoveryPlatformMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForMor106Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |